Oregovomab is under clinical development by OncoQuest and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Oregovomab’s likelihood of approval (LoA) and phase transition for Epithelial Ovarian Cancer took place on 29 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Oregovomab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Oregovomab is under development for the treatment of ovarian cancer, pancreatic ductal adenocarcinoma, fallopian tube cancer, peritoneal cancer, serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma and malignant Brenner's Tumor. Oregovomab is a murine monoclonal antibody. The drug candidate is administered through the intravenous route. It targets the circulating tumor-associated antigen CA125 (cancer antigen 125).
OncoQuest., is a developer of immunotherapeutic products for the treatment of cancer. The company is headquartered in Canada.
Quick View Oregovomab LOA Data
|Highest Development Stage|